Cited by 1,635Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesFerroptosis and cancer prognosis

The DOI matches its Crossref record; 70 of the 76 references it cites were found in a registry or an index.

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

Open access

Gibney, Geoffrey T, Weiner, Louis M, Atkins, Michael B·2016·The Lancet Oncology

DOI 10.1016/s1470-2045(16)30406-5PMC PMC5702534

Open this paper in CoChat — free account

Abstract

The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an exciting era of anticancer therapy. Durable responses can be seen in patients with melanoma and other malignancies. Although monotherapy with PD-1 or PD-L1 agents are typically well tolerated, the risk of immune-related adverse events increases with combination regimens. The development of predictive biomarkers is needed to optimise patient benefit, minimise risk of toxicities, and guide combination approaches. The greatest focus has been on tumour-cell PD-L1 expression. Although PD-L1 positivity enriches for populations with clinical benefit, PD-L1 testing alone is insufficient for patient selection in most malignancies. In this Review, we discuss the status of PD-L1 testing and explore emerging data on new biomarker strategies with tumour-infiltrating lymphocytes, mutational burden, immune gene signatures, and multiplex immunohistochemistry. Future development of an effective predictive biomarker for checkpoint inhibitor-based immunotherapy will integrate multiple approaches for optimal characterisation of the immune tumour microenvironment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(16)30406-5

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citation
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

Show all 76 references

Sorted by citations

Items 501–600 of 1,002

Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma
Gambichler, T., Gnielka, M., Rüddel, I., Stockfleth, E., Stücker, M., & Schmitz, L. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2015-x · Cited by 33
Implementing precision cancer medicine in the genomic era
Chen, H., Bonneville, R., & Roychowdhury, S. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.05.009 · Cited by 34
Identifying tumour microenvironment-related signature that correlates with prognosis and immunotherapy response in breast cancer
Zhao, H., Yin, X., Wang, L., Liu, K., Liu, W., Bo, L., & Wang, L. (2023) · Scientific Data · doi:10.1038/s41597-023-02032-2 · Cited by 38
Artificial intelligence-based digital pathology using H&E-stained whole slide images in immuno-oncology: from immune biomarker detection to immunotherapy response prediction
Zhang, J., Choi, H., Kim, Y., Park, J., Cho, S., Kim, E., Cho, A., Lee, J. Y., Choi, J., Low, C., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011346 · Cited by 34
Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond
Lin, E. M., Gong, J., Klempner, S. J., & Chao, J. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i25.2686 · Cited by 32
Circulating biomarkers predictive of tumor response to cancer immunotherapy
Lee, E. Y., & Kulkarni, R. P. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1659728 · Cited by 33
TIM‑3 expression and its association with overall survival in primary osteosarcoma
Pu, F., Chen, F., Zhang, Z., Qing, X., Lin, H., Zhao, L., Xia, P., & Shao, Z. (2019) · Oncology Letters · doi:10.3892/ol.2019.10855 · Cited by 33
Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1
Cimas, F. J., Manzano, A., Baliu‐Piqué, M., García, E. G., Pérez‐Segura, P., Nagy, Á. M., Pandiella, A., Győrffy, B., & Ocaña, A. (2020) · Cancers · doi:10.3390/cancers12082243 · Cited by 31
Therapeutic Perspectives in the Systemic Treatment of Kaposi’s Sarcoma
Valantin, M., Royston, L., Hentzien, M., Jary, A., Makinson, A., Veyri, M., Brégigeon, S., Isnard, S., Palich, R., & Routy, J. (2022) · Cancers · doi:10.3390/cancers14030484 · Cited by 32
Immunotherapy approaches for hematological cancers
Lanier, O. L., Pérez‐Herrero, E., Andrea, A. P. D. ’., Bahrami, K., Lee, E. Y. P., Ward, D. M., Ayala-Suárez, N., Rodríguez-Méndez, S. M., & Peppas, N. A. (2022) · iScience · doi:10.1016/j.isci.2022.105326 · Cited by 36
Multiplex Digital Immunoassays with Reduced Pre-partition Reaction via Massively Parallel Reagent Delivery on a Bead-Based SlipChip
Lyu, W., Yi, J., Guo, Q., Wang, Y., Zhang, J., Sun, T., Ma, H., Tang, T., Quan, X., Xu, H. Y., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c03044 · Cited by 31
Current state of immune checkpoints therapy for glioblastoma
Wang, H., Yang, J., Li, X., & Hai, Z. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24729 · Cited by 36
Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy
Zhang, M., Yang, H. J., Hua, W., Zhong, L., Xu, Z., & Qian, Q. (2019) · Frontiers of Medicine · doi:10.1007/s11684-018-0678-0 · Cited by 33
NMF-RI: blind spectral unmixing of highly mixed multispectral flow and image cytometry data
Jiménez‐Sánchez, D., Ariz, M., Morgado, J. M., Cortés‐Domínguez, I., & Ortíz-de-Solórzano, C. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz751 · Cited by 31
Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma
Bao, X., Shi, R., Zhao, T., & Wang, Y. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01908-9 · Cited by 31
Exploiting the obesity-associated immune microenvironment for cancer therapeutics
Desharnais, L., Walsh, L. A., & Quail, D. F. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107923 · Cited by 31
T Cells Retain Pivotal Antitumoral Functions under Tumor-Treating Electric Fields
Diamant, G., Simchony, H., Gasri-Plotnitsky, L., Roitman, M., Shiloach, T., Levin, A. G., Eshhar, Z., Haim, O., Pencovich, N., Grossman, R., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100100 · Cited by 33
Development of a Novel Immune Infiltration-Based Gene Signature to Predict Prognosis and Immunotherapy Response of Patients With Cervical Cancer
Yu, S., Li, X., Zhang, J., & Wu, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.709493 · Cited by 31
Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic Cancers
Noh, J. J., Kim, M. K., Choi, M. C., Lee, J., Park, H., Jung, S. G., Joo, W. D., Song, S. H., & Lee, C. M. (2021) · Cancer Research and Treatment · doi:10.4143/crt.2021.828 · Cited by 31
Integrative genomic and transcriptomic analysis reveals immune subtypes and prognostic markers in ovarian clear cell carcinoma
Ye, S., Li, Q., Wu, Y., Jiang, W., Zhou, S., Zhou, X., Yang, W., Tu, X., Shan, B., Huang, S., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01705-w · Cited by 31
Association between Nutritional Status and Treatment Response and Survival in Patients Treated with Immunotherapy for Lung Cancer: A Retrospective French Study
Gouez, M., Delrieu, L., Bouleuc, C., Girard, N., Raynard, B., & Marchal, T. (2022) · Cancers · doi:10.3390/cancers14143439 · Cited by 31
Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: A systematic review
Zhao, Z., Wang, X., Bao, X.-Q., Ning, J., Shang, M., & Zhang, D. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02699-1 · Cited by 30
Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects
Roudi, R., D’Angelo, A., Sirico, M., & Sobhani, N. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108322 · Cited by 31
Immune Checkpoint Inhibitors: Fundamental Mechanisms, Current Status and Future Directions
Younis, A., & Gribben, J. G. (2024) · Immuno · doi:10.3390/immuno4030013 · Cited by 34
Positive Immuno-Modulation Following Radiofrequency Assisted Liver Resection in Hepatocellular Carcinoma
Huang, K., Jayant, K., Lee, P., Yang, P.-C., Hsiao, C., Habib, N., & Sodergren, M. H. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030385 · Cited by 30
Addressing the Challenges of High‐Throughput Cancer Tissue Proteomics for Clinical Application: ProCan
Tully, B., Balleine, R. L., Hains, P. G., Zhong, Q., Reddel, R. R., & Robinson, P. J. (2019) · PROTEOMICS · doi:10.1002/pmic.201900109 · Cited by 30
Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer
Park, W., Mezquita, L., Okabe, N., Chae, Y. K., Kwon, D., Saravia, D., Auclin, É., Planchard, D., Caramella, C., Ferrara, R., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0643-y · Cited by 31
Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection
Iivanainen, S., & Koivunen, J. P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020556 · Cited by 30
The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation
Humphries, M. P., Craig, S. G., Kacprzyk, R., Fisher, N. C., Bingham, V., McQuaid, S., Murray, G. I., McManus, D. T., Turkington, R. C., James, J. A., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06987-y · Cited by 30
Impact of CT-based body composition parameters at baseline, their early changes and response in metastatic cancer patients treated with immune checkpoint inhibitors
Crombé, A., Kind, M., Toulmonde, M., Italiano, A., & Cousin, S. (2020) · European Journal of Radiology · doi:10.1016/j.ejrad.2020.109340 · Cited by 30
Development of a nanobody-based immunoassay for the sensitive detection of fibrinogen-like protein 1
Zhang, W., Liu, T., Wu, M., Chen, X., Li, H., Shi, Z., Li, Y., Li, X.-Y., Xu, H., Gong, L., et al. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00574-4 · Cited by 31
Tumor Immune Microenvironment Characterization in Hepatocellular Carcinoma Identifies Four Prognostic and Immunotherapeutically Relevant Subclasses
Gao, X., Huang, H., Wang, Y., Pan, C., Yin, S., Zhou, L., & Zheng, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.610513 · Cited by 30
Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab
Shang, X., Li, Z., Sun, J., Zhao, C., Lin, J., & Wang, H. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.02.010 · Cited by 30
Characterization of Circulating T Cell Receptor Repertoire Provides Information about Clinical Outcome after PD-1 Blockade in Advanced Non-Small Cell Lung Cancer Patients
Dong, N., Moreno‐Manuel, A., Fariñas, S. C., Gallach, S., Zhang, F., Blasco, A., Aparisi, F., Meri-Abad, M., Guijarro, R., Sirera, R., et al. (2021) · Cancers · doi:10.3390/cancers13122950 · Cited by 28
Current advances in immune checkpoint inhibitor combinations with radiation therapy or cryotherapy for breast cancer
Ho, A. Y., Tabrizi, S., Dunn, S. A., & McArthur, H. L. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06408-z · Cited by 30
SLAMF8 expression predicts the efficacy of anti‐PD1 immunotherapy in gastrointestinal cancers
Zhang, Q., Cheng, L., Qin, Y., Kong, L., Shi, X., Hu, J. Y., Li, L., Ding, Z., Wang, T., Shen, J., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1347 · Cited by 30
Evaluation of autoantibodies as predictors of treatment response and immune‐related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan‐cancer study
Barth, D. A., Stanzer, S., Terzic, J. A., Bauernhofer, T., Absenger, G., Posch, F., Lipp, R., Halm, M., Szkandera, J., Balić, M., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4675 · Cited by 29
Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer
de Ruiter, B.-M., van Hattum, J. W., Lipman, D., de Reijke, T. M., van Moorselaar, R. J. A., van Gennep, E. J., Piet, A. H. M., Donker, M., van der Hulle, T., Voortman, J., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.07.009 · Cited by 31
Role of immune microenvironment in gastrointestinal stromal tumours
Blakely, A. M., Matoso, A., Patil, P. A., Taliano, R., Machan, J. T., Miner, T. J., Lombardo, K. A., Resnick, M. B., & Wang, L. (2017) · Histopathology · doi:10.1111/his.13382 · Cited by 30
Can radiomics personalise immunotherapy?
Naqa, I. E., & Haken, R. K. T. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30429-7 · Cited by 30
Meta-analysis of tumor and T cell intrinsic mechanisms of sensitization to checkpoint inhibitionPreprint
Litchfield, K., Reading, J. L., Puttick, C., Abbosh, C., Bentham, R. B., Watkins, T. B. K., Rosenthal, R., Biswas, D., Lim, E. L., Bakir, M. A., et al. (2020) · doi:10.21203/rs.3.rs-76468/v1 · Cited by 32
Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma
Peng, C., & Cohen, D. J. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1813278 · Cited by 29
Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials
Yu, J., Li, M., Ren, B., Cheng, L., Wang, X., Ma, Z., Yong, W. P., Chen, X., Wang, L., & Goh, B. C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1261575 · Cited by 31
IMPROVE: a feature model to predict neoepitope immunogenicity through broad-scale validation of T-cell recognition
Borch, A., Carri, I., Reynisson, B., Alvarez, H. M. G., Munk, K. K., Montemurro, A., Kristensen, N. P., Tvingsholm, S. A., Holm, J. S., Heeke, C., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1360281 · Cited by 26
Body composition derangements in lung cancer patients treated with first‐line pembrolizumab: A multicentre observational study
Trestini, I., Belluomini, L., Dodi, A., Sposito, M., Caldart, A., Kadrija, D., Pasqualin, L., Riva, S. T., Scaglione, I. M., Tregnago, D., et al. (2024) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13568 · Cited by 29
Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC
Jiang, T., Li, X., Wang, J., Su, C., Han, W., Zhao, C., Wu, F., Gao, G., Li, W., Chen, X., et al. (2017) · Theranostics · doi:10.7150/thno.21687 · Cited by 29
The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment
Brighi, N., Farolfi, A., Conteduca, V., Gurioli, G., Gargiulo, S., Gallá, V., Schepisi, G., Lolli, C., Casadei, C., & Giorgi, U. D. (2019) · Cancers · doi:10.3390/cancers11121935 · Cited by 28
The Potential of Immune Checkpoint Blockade in Cervical Cancer: Can Combinatorial Regimens Maximize Response? A Review of the Literature
Chitsike, L., & Duerksen-Hughes, P. J. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00790-4 · Cited by 29
Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model
Pan, X. H., Yi, M., Liu, C., Jin, Y. T., Liu, B., Hu, G., & Yuan, X. (2022) · Bioengineered · doi:10.1080/21655979.2022.2029236 · Cited by 30
Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancer
Masuhiro, K., Tamiya, M., Fujimoto, K., Koyama, S., Naito, Y., Osa, A., Hirai, T., Suzuki, H., Okamoto, N., Shiroyama, T., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.157915 · Cited by 30
A nanoformulation for immunosuppression reversal and broad-spectrum self-amplifying antitumor ferroptosis-immunotherapy
Yang, Q., Liu, T., Zheng, H., Zhou, Z., Huang, Y., Jia, H., Fu, S., Zhang, X., Zhang, H., Liu, Y., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121936 · Cited by 29
Tumor-infiltrating lymphocyte enrichment predicted by CT radiomics analysis is associated with clinical outcomes of non-small cell lung cancer patients receiving immune checkpoint inhibitors
Park, C., Jeong, D. Y., Choi, Y., Oh, Y. J., Kim, J., Ryu, J., Paeng, K., Lee, S., Ock, C., & Lee, H. Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1038089 · Cited by 30
Molecular analysis of circulating tumors cells: Biomarkers beyond enumeration
Hwang, W. L., Pleskow, H. M., & Miyamoto, D. T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.003 · Cited by 30
TRAIL receptor-induced features of epithelial-to-mesenchymal transition increase tumour phenotypic heterogeneity: potential cell survival mechanisms
Peyre, L., Meyer, M., Hofman, P. M., & Roux, J. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01177-w · Cited by 31
Molecular mechanisms of cisplatin resistance in ovarian cancer
Jiang, C., Shen, C., Ni, M., Huang, L., Hu, H., Dai, Q. Y., Zhao, H., & Zhu, Z. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.06.032 · Cited by 33
Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma
Tomlinson, J. L., Li, B., Yang, J., Loeuillard, E. J., Stumpf, H. E., Kuipers, H., Watkins, R. D., Carlson, D. M., Willhite, J., O’Brien, D. R., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.02.008 · Cited by 30
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Polcaro, G., Liguori, L., Manzo, V., Chianese, A., Donadio, G., Caputo, A., Scognamiglio, G., Dell’Annunziata, F., Langella, M., Corbi, G., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01976-2 · Cited by 29
Targeted Therapies for Melanoma Brain Metastases
Berghoff, A. S., & Preusser, M. (2017) · Current Treatment Options in Neurology · doi:10.1007/s11940-017-0449-2 · Cited by 28
Immune Gene Expression Profile in Hepatocellular Carcinoma and Surrounding Tissue Predicts Time to Tumor Recurrence
Carone, C., Olivani, A., Valle, R. D., Manuguerra, R., Silini, E. M., Trenti, T., Missale, G., & Cariani, E. (2018) · Liver Cancer · doi:10.1159/000486764 · Cited by 29
Societal challenges of precision medicine: Bringing order to chaos
Salgado, R., Moore, H. M., Martens, J. W. M., Lively, T., Malik, S. M., McDermott, U., Michiels, S., Moscow, J. A., Tejpar, S., McKee, T. C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.028 · Cited by 29
Importance of choice of materials and methods in PD‐L1 and TIL assessment in oropharyngeal squamous cell carcinoma
Meulenaere, A. D., Vermassen, T., Creytens, D., Aspeslagh, S., Deron, P., Duprez, F., Rottey, S., Dorpe, J. V., & Ferdinande, L. (2018) · Histopathology · doi:10.1111/his.13650 · Cited by 26
Computed Tomography-Derived Radiomic Metrics Can Identify Responders to Immunotherapy in Ovarian Cancer.
Himoto, Y., Veeraraghavan, H., Zheng, J.-T., Zamarin, D., Snyder, A., Capanu, M., Nougaret, S., Vargas, H., Shitano, F., Callahan, M., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00038 · Cited by 23
DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients’ survival, immune cell infiltrates, mutational load, and interferon γ signature
Sailer, V. W., Sailer, U., Bawden, E., Zarbl, R., Wiek, C., Vogt, T. J., Dietrich, J., Loick, S., Grünwald, I., Toma, M. I., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.09.038 · Cited by 28
PD‐L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non‐small cell lung cancer?
Dong, A., Zhao, Y., Li, Z., & Hu, H. (2020) · The Journal of Gene Medicine · doi:10.1002/jgm.3294 · Cited by 29
Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma
Liu, X., Wang, F., Xu, C., Chen, X., Hou, X., Li, Q., Li, P., Xie, Z., Liu, Y., Chang, L., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01573-9 · Cited by 29
Survival prediction and response to immune checkpoint inhibitors: A prognostic immune signature for hepatocellular carcinoma
Xu, Y., Wang, Z., & Li, F. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100957 · Cited by 30
Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis
Espósito, A., Marra, A., Bagnardi, V., Frassoni, S., Morganti, S., Viale, G., Zagami, P., Varano, G. M., Buccimazza, G., Orsi, F., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2020.12.028 · Cited by 28
Research progress on immunotherapy in triple‑negative breast cancer (Review)
Zhang, X., Ge, X., Jiang, T., Yang, R., & Li, S. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5385 · Cited by 28
Nanohydroxyapatite Stimulates PD-L1 Expression to Boost Melanoma Combination Immunotherapy
Yang, Y., Cui, Y., Cao, W., Zhao, M., Lin, W., Xu, R., Yang, X., Chen, Y., Li, H., Liang, J., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c07818 · Cited by 28
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance
Pelizzaro, F., Farinati, F., & Trevisani, F. (2023) · Biomedicines · doi:10.3390/biomedicines11041020 · Cited by 28
A Predictive Network‐Based Immune Checkpoint Blockade Immunotherapeutic Signature Optimizing Patient Selection and Treatment Strategies
Zhang, N., Yang, M., Yang, J., Zhang, C., & Guo, A. (2024) · Small Methods · doi:10.1002/smtd.202301685 · Cited by 27
Caspase-1 from Human Myeloid-Derived Suppressor Cells Can Promote T Cell–Independent Tumor Proliferation
Zeng, Q., Fu, J. L., Korrer, M. J., Gorbounov, M., Murray, P. J., Pardoll, D., Masica, D. L., & Kim, Y. J. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0543 · Cited by 26
Response to Checkpoint Inhibitor Therapy in Advanced Classic Kaposi Sarcoma: A Case Report and Immunogenomic Study
Saller, J. J., Walko, C. M., Millis, S. Z., Henderson‐Jackson, E., Makanji, R. J., & Brohl, A. S. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7018 · Cited by 27
Telomerase and Telomeres Biology in Thyroid Cancer
Donati, B., & Ciarrocchi, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122887 · Cited by 29
Novel immune-related genes in the tumor microenvironment with prognostic value in breast cancer
Tan, W., Liu, M., Wang, L., Guo, Y., Wei, C., Zhang, S., Luo, C., & Liu, N. (2021) · BMC Cancer · doi:10.1186/s12885-021-07837-1 · Cited by 27
Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study
Vasiliadou, I., Breik, O., Baker, H., Leslie, I., Sim, V., Hegarty, G., Michaelidou, A., Nathan, K., Hartley, A. G. J., Good, J. S., et al. (2021) · Cancers · doi:10.3390/cancers13061413 · Cited by 27
Kaposi’s Sarcoma in Virally Suppressed People Living with HIV: An Emerging Condition
Palich, R., Makinson, A., Veyri, M., Guihot, A., Valantin, M., Brégigeon, S., Poizot‐Martin, I., Solas, C., Grabar, S., Martin‐Blondel, G., et al. (2021) · Cancers · doi:10.3390/cancers13225702 · Cited by 28
An aging‐related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma
Zhang, W., Li, Y., Lyu, J., Shi, F., Kong, Y., Sheng, C., Wang, S., & Wang, Q. (2021) · Cancer Science · doi:10.1111/cas.15254 · Cited by 26
C‐reactive protein flare‐response predicts long‐term efficacy to first‐line anti‐PD‐1‐based combination therapy in metastatic renal cell carcinoma
Klümper, N., Schmucker, P., Hahn, O., Hoeh, B., Mattigk, A., Banek, S., Ellinger, J., Heinzelbecker, J., Sikic, D., Eckstein, M., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1358 · Cited by 28
PRC2-Mediated Epigenetic Suppression of Type I IFN-STAT2 Signaling Impairs Antitumor Immunity in Luminal Breast Cancer
Hong, J., Lee, J. H., Zhang, Z., Wu, Y., Yang, M., Liao, Y., de la Rosa, R., Scheirer, J. L., Pechacek, D., Zhang, N., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0736 · Cited by 26
Lactate regulators contribute to tumor microenvironment and predict prognosis in lung adenocarcinoma
Shang, S., Wang, M.-Z., Xing, Z., He, N., & Li, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1024925 · Cited by 27
Is the combination of immunotherapy with conventional chemotherapy the key to increase the efficacy of colorectal cancer treatment?
Olguín, J. E., Mendoza-Rodríguez, M., Sánchez-Barrera, C. Á., & Terrazas, L. I. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i2.251 · Cited by 30
Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma
Zhao, B., Wu, J., Li, H., Wang, Y., Wang, Y., Xing, H., Wang, Y., & Ma, W. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01098-0 · Cited by 27
A robust response to combination immune checkpoint inhibitor therapy in HPV-related small cell cancer: a case report
Ho, W. J., Rooper, L. M., Sagorsky, S., & Kang, H. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0348-4 · Cited by 27
Fresh Tissue Multi-omics Profiling Reveals Immune Classification and Suggests Immunotherapy Candidates for Conventional Chondrosarcoma
Li, B., Li, G., Yan, X., Zhu, D., Lin, P. P., Wang, Z., Qu, H., He, X., Fu, Y., Zhu, X., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1893 · Cited by 28
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study
Bersanelli, M., Cortellini, A., Leonetti, A., Parisi, A., Tiseo, M., Bordi, P., Michiara, M., Bui, S., Cosenza, A., Ferri, L., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03522-3 · Cited by 26
Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC
Liu, J., Cai, Y., He, Y.-Z., Xu, J., Tian, S.-F., & Li, Z. (2024) · BMC Cancer · doi:10.1186/s12885-024-11875-w · Cited by 28
Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification
Chen, M., Andreozzi, M., Pockaj, B. A., Barrett, M. T., Ocal, I. T., McCullough, A. E., Linnaus, M. E., Chang, J. M., Yearley, J. H., Annamalai, L., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.86 · Cited by 26
Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review
Yang, K., Li, J., Sun, Z., Zhao, L., & Bai, C. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920975353 · Cited by 26
Human cancer germline antigen-specific cytotoxic T cell—what can we learn from patient
Hamid, M. A., Peng, Y., & Dong, T. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0468-x · Cited by 27
A novel predictive model incorporating immune-related gene signatures for overall survival in melanoma patients
Liao, M., Zeng, F., Li, Y., Gao, Q., Yin, M., Deng, G., & Chen, X. (2020) · Scientific Reports · doi:10.1038/s41598-020-69330-2 · Cited by 26
In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer
Rojas, K., Baliu‐Piqué, M., Manzano, A., Sáiz-Ladera, C., García‐Barberán, V., Cimas, F. J., Pérez‐Segura, P., Pandiella, A., Győrffy, B., & Ocaña, A. (2021) · Cellular Oncology · doi:10.1007/s13402-020-00583-9 · Cited by 27
Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study
Herbreteau, G., Vallée, A., Knol, A., Théoleyre, S., Quereux, G., Varey, É., Khammari, A., Dréno, B., & Denis, M. G. (2021) · Cancers · doi:10.3390/cancers13081826 · Cited by 26
Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy
Wang, T., Denman, D., Bacot, S. M., & Feldman, G. M. (2022) · Biomedicines · doi:10.3390/biomedicines10051181 · Cited by 27
Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma
Xu, F., Guan, Y., Zhang, P., Li, X., Ma, Y., Gao, M., Chong, T., & Ren, B. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01017-3 · Cited by 26
Exploiting the role of T cells in the pathogenesis of Sjögren’s syndrome for therapeutic treatment
An, Q., Zhao, J., Zhu, X., Yang, B., Wu, Z., Su, Y., Zhang, L., Xu, K., & Ma, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.995895 · Cited by 26
RNF173 suppresses RAF/MEK/ERK signaling to regulate invasion and metastasis via GRB2 ubiquitination in Hepatocellular Carcinoma
Zhou, J., Tu, D., Peng, R., Tang, Y., Deng, Q., Su, B., Wang, S., Tang, H., Jin, S., Jiang, G., et al. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01241-x · Cited by 26
Molecular pathology of non‐small cell carcinoma
Yatabe, Y. (2023) · Histopathology · doi:10.1111/his.15080 · Cited by 30
Nivolumab maintenance after salvage autologous stem cell transplantation results in long‐term remission in multiple relapsed primary CNS lymphoma
Terziev, D., Hutter, B., Klink, B., Stenzinger, A., Stögbauer, F., Glimm, H., Fröhling, S., Wickenhauser, C., Jordan, K., Hurtz, H.-J., et al. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13072 · Cited by 26
Impact of PD‐L1, transforming growth factor‐β expression and tumor‐infiltrating CD8+ T cells on clinical outcome of patients with advanced thymic epithelial tumors
Duan, J., Liu, X., Chen, H., Sun, Y., Liu, Y., Bai, H., & Wang, J. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12826 · Cited by 26

Authors: Gibney, G. T., Weiner, L. M., & Atkins, M. B.
Affiliations: Georgetown University Medical Center (US)
Corresponding author: Gibney, Geoffrey T
ORCID: Gibney, Geoffrey T
Weiner, Louis M
Atkins, Michael B
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2016-12
Volume: 17
Issue: 12
Pages: e542-e551
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(16)30406-5
PMC: PMC5702534
OpenAlex: W2559382297
Cited by: 1,635
References: 76
Citations by year: 2026: 62 · 2025: 111 · 2024: 161 · 2023: 222 · 2022: 238 · 2021: 229 · 2020: 248 · 2019: 171 · 2018: 109 · 2017: 83
FWCI: 11.76
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA050633, P30CA051008)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords: predictive biomarkers, immune checkpoint inhibitors, PD-1, PD-L1 expression, tumor-infiltrating lymphocytes, tumor mutational burden, immune-related gene signature, multiplex immunohistochemistry, immune-related adverse events, patient selection, melanoma
MeSH terms: Humans, Immunohistochemistry, Immunotherapy, Neoplasms, Biomarkers, Lymphocytes, Tumor-Infiltrating, Tumor Microenvironment, Cell Cycle Checkpoints, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks